Physician profile
Peter Lam
NPI 1346624111
$8,168.03
in general payments reported to CMS, 2019-2025
18 companies · $931 in 2025
The $931 reported for 2025 was more than what 75% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $904 · 2020: $171 · 2021: $106 · 2022: $1,124 · 2023: $1,058 · 2024: $3,874 · 2025: $931.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,776 · Consulting Fee: $1,500 · Travel and Lodging: $1,212 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,775.57 |
| Consulting Fee | $1,500.00 |
| Travel and Lodging | $1,212.01 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $375.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $2,043.62 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $1,544.93 | 2024-2025 | Teneo, Envista Aspire Iol, Stellaris Elite |
| Alcon Vision LLC | $1,387.21 | 2019-2025 | Clareon, Unity, Clareon Panoptix Pro |
| Biotissue Holdings INC. | $1,167.87 | 2021-2025 | |
| Abbvie INC. | $620.86 | 2022-2025 | |
| Rxsight INC | $401.07 | 2021-2025 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Sight Sciences, INC. | $214.22 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $157.40 | 2023-2025 | Eylea Hd |
| Glaukos Corporation | $148.65 | 2023 | |
| Aerie Pharmaceuticals, INC. | $123.92 | 2019 | |
| Novartis Pharmaceuticals Corporation | $74.03 | 2022-2023 | |
| Dompe US, INC. | $68.19 | 2022-2025 | Oxervate |
| Ocular Therapeutix, INC. | $55.43 | 2023-2024 | Dextenza |
| Allergan, INC. | $42.75 | 2021-2022 | |
| Alimera Sciences, INC. | $39.11 | 2023-2024 | Iluvien, Yutiq |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $38.44 | 2023-2024 | Vabysmo |
| Apellis Pharmaceuticals, INC. | $21.19 | 2023 | Syfovre |
| Kala Pharmaceuticals, INC. | $19.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Lam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.